STERIS’ (TSE:STE – Free Report) – Investment analysts at Raymond James issued their FY2027 earnings estimates for shares of STERIS’ in a research report issued on Wednesday, March 12th. Raymond James analyst M. Barth anticipates that the company will post earnings per share of $0.63 for the year. Raymond James also issued estimates for STERIS’’s FY2028 earnings at $0.66 EPS.
Several other brokerages also recently issued reports on STE. Atb Cap Markets upgraded shares of STERIS’ to a “strong-buy” rating in a research note on Sunday, December 22nd. Cormark upgraded shares of STERIS’ to a “moderate buy” rating in a research note on Monday, January 6th.
STERIS’ Stock Performance
STERIS’ Company Profile
STERIS’s MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science product and service solutions around the globe by providing innovative healthcare and life science product and service solutions around the globe.
See Also
- Five stocks we like better than STERIS’
- How to trade using analyst ratings
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- 3 Must-Own Stocks to Build Wealth This Decade
- What Are Dividend Challengers?
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for STERIS’ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS’ and related companies with MarketBeat.com's FREE daily email newsletter.
